Axsome has reached a settlement with Hikma Pharmaceuticals to settle a legal dispute over a patent concerning Sunosi.
Following the FDA's comments, Axsome intends to file a supplemental NDA for AXS-05 to treat agitation in Alzheimer's disease in the third quarter of 2025.
On Monday, Axsome Therapeutics, Inc. (AXSM) revealed that the EMERGE Phase 3 trial for Symbravo (MoSEIC meloxicam and rizatriptan) successfully achieved its main goal. This trial involved patients who did not respond well to oral CGRP inhibitors, which are the most frequently prescribed medications for migraines.
Axsome Therapeutics, Inc. (NASDAQ:AXSM) held its Q4 2024 Earnings Conference Call on February 18, 2025, at 8:00 AM ET. The call featured key company participants, including CEO Herriot Tabuteau and CFO Nick Pizzie, along with various analysts from different financial firms. The operator welcomed everyone to the conference call, marking the start of the discussion.
Axsome Therapeutics (AXSM) reported a quarterly loss of $0.96 per share, which is better than the Zacks Consensus Estimate of a $1 loss. This is also a larger loss compared to the $0.73 per share loss from the same period last year.
On Tuesday, February 18, biopharmaceutical company Axsome Therapeutics (AXSM -0.40%) announced its earnings for the fourth quarter and the entire year of 2024, which were somewhat mixed. The company saw significant revenue growth, with sales reaching $118.8 million, exceeding analysts' expectations of $118 million.
In the fourth quarter of 2024, AXSM's earnings fell short of expectations, but their revenues exceeded them. Additionally, net product sales increased compared to the previous year.
This week, we will examine five biotech and pharmaceutical companies: AXSM, HALO, FOLD, BMRN, and INSM, which are expected to announce their fourth-quarter results for 2024.
Even though it's only mid-February, biotech firm Axsome Therapeutics (AXSM -0.40%) has already increased by 55% this year. Significant stock market increases in a short time are not uncommon in this sector.
Axsome Therapeutics (NASDAQ: AXSM) saw its shares rise on Tuesday, even as the S&P 500 and Nasdaq Composite both dropped by 0.3%. This increase followed a senior analyst at Mizuho, a major Japanese bank, raising his price target for Axsome after the company resolved a key legal issue. The news was shared with investors on Monday.